cobas^® CMV

Enhancing the picture of CMV control

Cytomegalovirus (CMV) is a leading cause of morbidity and mortality in transplant recipients. Severe CMV infection in high-risk patients may develop soon after transplantation and, without effective treatment, may lead to CMV syndrome, tissue invasive disease, and potential rejection or loss of the graft.

The cobas^® CMV reliably monitors CMV infection and is proven to provide comparable and reproducible viral load results across different institutions to reliably spot CMV and help transplant patients thrive. You can realise the following benefits for your laboratory and clinicians.

• Standardization
  
  The cobas^® CMV demonstrates co-linearity to the WHO international standard, reporting results in IU/mL as recommended by the international consensus guidelines for CMV management in solid organ transplant patients.1,2 It helps bring standardisation to sample type (plasma) for testing and delivers results that align across institutions to optimise CMV management.


• Clinical Validation
  
  The cobas^® CMV offers the proven advantages of a clinically validated test. Roche CMV tests have been central in clinical studies for current treatment regimens and those in development. Extensive studies were conducted in the development of cobas^® CMV, including clinical trials required to demonstrate clinical utility for FDA submission.


• Automation
  
  The generation and maintenance of an LDT takes time and effort on the part of the laboratory, and places the burden and associated risk for quality compliance and troubleshooting on the laboratory. The cobas^® CMV (CE-IVD) is validated with ready-to-use reagents, performed on a fully automated platform solutions that include calibration.3,4

• Co-linearity to the WHO international standard and reports in IU/mL
• Tight precision at medically relevant decision points
• Confidence in your results with primers and probes targeting highly conserved regions not impacted by drug resistance mutations